Molecular MOLN 深 沪
已收盘 08-21 16:00:00 美东时间
4.3999
+0.170
+4.02%
华盛通- 最 高4.3999
- 今 开4.38
- 成交量 504股
- 最 低 4.38
- 昨 收 4.23
- 总市值 1.65亿
- 52周最高 5.36
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.53
- 委 比 90.07%
- 总股本 3751.12万
- 历史最高 32.04
- 量 比 0.35
- 振 幅 0.47%
- 历史最低 3.32
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Quanome Technologies Establishes Global Quantum Council and Scientific Advisory Network
<p>Quanome Technologies, Inc. announced the establishment of its Global Quantum Council and Scientific Advisory Network to advance quantum science and its applications across industries. The initiative focuses on four streams: Quantum Systems, Molecular Discovery, Advanced Nuclear Technologies, and Quantum-Safe Cybersecurity. These platforms aim to foster collaboration, identify impactful technologies, and contribute to societal and economic prog...
08-20 14:27
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
AEON Biopharma announced progress in ABP-450's development as a BOTOX biosimilar, achieving 98% sequence coverage with 100% amino acid identity and confirming the critical C430-C454 disulfide bond. FDA feedback from an upcoming Type 2b meeting will guide future clinical studies, supporting the molecule's potential for full U.S. market entry.
08-19 12:00
Insight Molecular Diagnostics To Host Virtual KOL Event On August 17 To Discuss GraftAssure Platform Leveraging Digital PCR Technology For Reliable dd-cfDNA Results In Transplanted Organ Health Monitoring
Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026 at 11AM ET featuring Max Jacob Liebo, MD (Loyola University Medical Center), who will join Nick Ioannou, MD, MHA (iMDx VP Medical Affairs) ...
08-12 04:17
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aura Biosciences reported Q2 2026 financial results and business updates, highlighting the full enrollment of its Phase 3 CoMpass trial for bel-sar in early choroidal melanoma, exceeding targets and on track for 2H 2027 topline data. The company refocused its strategic plan on ocular oncology, deprioritizing the NMIBC program while maintaining data collection. Organizational restructuring and leadership appointments were announced to align resour...
08-11 11:00
CORRECTION: Insight Molecular Q2 Adj. EPS $(0.23) Beats $(0.24) Estimate, Sales $239.000K Miss $437.500K Estimate
Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 23.33 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $239.000 thou...
08-11 06:24
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
MIRA Pharmaceuticals announced positive toxicokinetic findings for SKNY-1 in a 7-day study in Beagle dogs, showing rapid absorption and dose-dependent systemic exposure, supporting dose selection and IND-enabling development. SKNY-1 aims to treat obesity while preserving lean body mass, offering a potential advantage over current treatments.
08-06 12:00
SES Ai Enters Agreement With Doroni Aerospace To Design And Deliver A Battery Pack For Doroni's H1-X e VTOL Worth Up To $1.09M, Of Which Initial Tranche Of $65K Is Committed
Under the framework agreement, upon issuance of purchase orders from Doroni, SES AI will design and develop H1-X battery systems to power the aircraft’s ground and flight-test campaign — building a path to H1-X testing as early as 2027. The agreement includes options to expand into additional test s...
08-03 19:18
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
Ascentage Pharma appoints Faiçal Miyara, PhD, as Chief Business Officer and Jim Ziegler as Chief Commercial Officer to strengthen global business development and U.S. commercialization efforts. Miyara brings over 20 years of oncology-focused business development experience, while Ziegler has 25 years of expertise in biopharmaceutical commercialization. The appointments aim to accelerate the company's global expansion and enhance its commercial ca...
08-02 23:30
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
MIRA Pharmaceuticals announced progress in its preclinical programs MIRA-55 (chronic inflammatory pain) and SKNY-1 (obesity and addiction). The company completed 7-day toxicology and pharmacokinetic studies in rats and dogs, supporting future GLP-compliant studies. CMC activities and formulation optimization are ongoing to advance both candidates toward IND-enabling development. MIRA-55 and SKNY-1 demonstrate promising preclinical results, with M...
07-30 12:00
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
Radiopharm Theranostics announced positive results from its Phase 2b trial of RAD101 for diagnosing suspected recurrent brain metastases. The trial showed 93% concordance between RAD101 PET and MRI imaging, meeting the primary endpoint. Sensitivity was 86% in 14 patients with follow-up data, with specificity results expected in Q4 2026. The company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026. The imaging Brain Metastases ...
07-22 11:00
